Reported results
- Revenue was $0.3 million for the three months ended September 30, 2026.
- Research and development expenses were $23.6 million for the three months ended September 30, 2026.
- Selling, general, and administrative expenses were $9.0 million for the three months ended September 30, 2026.
- Net loss was $33.3 million for the three months ended September 30, 2026.
- Cash, cash equivalents, and marketable securities as of September 30, 2026 were $173.7 million.
Guidance
- Absci anticipates reporting 13-week interim proof-of-concept data from the HEADLINE trial in December 2026.
- Absci anticipates reporting full 26-week proof-of-concept data in early 2027.
- Absci anticipates initiation of the Phase 2 STORYLINE clinical trial in mid-2027.
- Absci believes its cash, cash equivalents, and marketable securities will be sufficient to fund its operating plans into the second half of 2028.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
